Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
6
Neutral
3
Bullish
5
Bearish
6
Neutral
3
Bullish
37
Bearish
0
Neutral
0
Bullish
32
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Influx Healthtech Limited is a contract development and manufacturing organization (CDMO) specializing in nutraceuticals, cosmetics, pet care, and homecare products.
The company reported a noteworthy 39% increase in revenue for H1 FY26, reaching INR 66.8 crores, driven mainly by its nutraceutical segment. Meanwhile, EBITDA rose by 61% during the same period.
Influx Healthtech plans strategic capacity expansion through IPO proceeds, targeting a 2.5x increase in capacity, which will significantly enhance their manufacturing capabilities across nutraceutical and veterinary divisions.
The company launched multiple new products across different categories, such as ayurvedic gummies and nutritional oral gels, reflecting a robust innovative pipeline and a focus on market trends.
Influx Healthtech has received several industry certifications, including GMP, NSF, and FDA approvals, which position it favorably for market expansion, particularly in export markets.
Pharmaceuticals & Biotechnology
Pharmaceuticals
557 Cr
High Risk
29.8
32.3
0.7
6.6
261.95
120.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Influx Healthtech Ltd (INFLUX) is currently trading at 240.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Influx Healthtech Limited is a contract development and manufacturing organization (CDMO) specializing in nutraceuticals, cosmetics, pet care, and homecare products. The company reported a noteworthy 39% increase in revenue for H1 FY26, reaching INR 66.8 crores, driven mainly by its nutraceutical segment. Meanwhile, EBITDA rose by 61% during the same period. Influx Healthtech plans strategic capacity expansion through IPO proceeds, targeting a 2.5x increase in capacity, which will significantly enhance their manufacturing capabilities across nutraceutical and veterinary divisions. The company launched multiple new products across different categories, such as ayurvedic gummies and nutritional oral gels, reflecting a robust innovative pipeline and a focus on market trends. Influx Healthtech has received several industry certifications, including GMP, NSF, and FDA approvals, which position it favorably for market expansion, particularly in export markets.
Over the past 52 weeks, Influx Healthtech Ltd has traded between a low of ₹120.00 and a high of ₹261.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Influx Healthtech Ltd has a market capitalization of approximately 556.54. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Influx Healthtech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 29.83 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 556.54 Cr, Influx Healthtech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Influx Healthtech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Influx Healthtech Ltd is 29.83. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Investor Presentation
Q2 FY26
Investor Presentation
Q4 FY25
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
469.65 | 685 Cr | 33.36 | 4.46 | 0.00 | 13.30 | 16.18 | 8.86 | ||
219.55 | 557 Cr | 29.83 | 6.61 | 0.00 | 0.00 | 0.00 | 15.55 | ||
109.19 | 506 Cr | 29.43 | 2.40 | 0.00 | 7.41 | 11.89 | 3.14 | ||
134.70 | 472 Cr | 17.78 | 1.78 | 0.00 | 10.38 | 11.71 | 6.23 | ||
1010.05 | 453 Cr | 13.75 | 2.47 | 1.75 | 18.04 | 24.68 | 15.51 | ||
72.32 | 427 Cr | 55.14 | 1.49 | 0.00 | 2.62 | 6.18 | 1.50 | ||
655.05 | 410 Cr | 38.92 | 1.04 | 0.70 | -3.83 | -3.33 | 1.80 | ||
| Median: 7 Co. | — | 219.55 | 472 Cr | 29.83 | 2.40 | 0.00 | 7.41 | 11.71 | 6.23 |
